XNAS
SAEN
Market cap31mUSD
Nov 05, Last price
0.65USD
1D
20.62%
1Q
-25.94%
IPO
-91.24%
Name
Genenta Science SPA
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
123.54%
Shs. 5Y
1.70%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-6m
L-32.63%
CFO
-7m
L+10.06%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors. Its activities and acquisition strategy covers aerospace, defense, national security, and biotechnology/biosecurity. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Key people
Richard Slansky
Chief Financial Officer · since 2021
Barbara Regonini
Finance Director · since 2021
Stefania Mazzoleni
Scientific Project Manager, Communication Officer · since 2016
Carlo Russo
Chief Medical Officer, Head of Development · since 2021
John Louis Cantello
Independent Director · since 2024
Lauren Haeyong Chung
Independent Director · since 2024
Independent Director · since 2021
Armon Reza Sharei
Independent Director · since 2024
Independent Director · since 2024
Headquarters & legal address
VIA DELL'ANNUNCIATA, 31 (MILANO)
MILANO, MI 20121
IT
MILANO, MI 20121
IT
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||